Ambra-1 and Loricrin as biomarkers for disease progression in melanoma
US10634678B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2015 |
| Grant date | Apr 28, 2020 |
| Priority date | — |
| Expiry date | Feb 23, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates inter alia to therapeutic agents for use in the treatment of melanoma, methods of diagnosing an increased risk of metastasis in a subject suffering from melanoma, methods of treating such subjects, diagnostic assays and kits. More particularly, in certain embodiments the invention relates to identifying whether a subject suffering from melanoma has an increased risk of metastasis by determining the expression of Ambra-1 and Loricrin in a tissue sample obtained from the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.